Zimmer Biomet Secures Exclusive License for NeuroOne's Brain Ablation System in Major Neurology Push

Zimmer Biomet has deepened its partnership with NeuroOne Medical Technologies by acquiring exclusive global distribution rights for the OneRF Ablation System, a groundbreaking radiofrequency device that targets neurological disorders. Under this agreement, NeuroOne will receive $3 million upfront with a potential $1 million milestone based on sales performance. Designed to identify and ablate the precise brain tissue associated with seizure activity, the OneRF System received FDA clearance in December, with a limited commercial rollout beginning in March. NeuroOne recently recorded about $826,000 in Q3 product revenue, with OneRF accounting for $163,000, marking it as a growing revenue stream that Zimmer’s distribution network may soon elevate.

​

Expanding on an initial 2020 agreement covering NeuroOne's cortical electrodes, Zimmer’s extended role could bring critical scale to OneRF’s adoption. NeuroOne has already implanted 16 patients across four U.S. centers, with sales quotes in progress for an additional 12 sites, signaling early demand. Amid its continued growth, NeuroOne has bolstered its finances with recent private placements and credit arrangements, pushing its operational funding through July 2025. With Zimmer's backing, the company aims to reach more patients and drive the future of neurology-focused radiofrequency ablation technology.